Platform antibody compositions

Abstract

The present invention provides novel compositions of human IgG 2 antibodies comprising a chelating agent. The present invention also provides novel antibody compositions that exhibit improved chemical and/or physical stability. Also provided are methods of treating diseases and conditions with compositions of human IgG 2 antibodies, including inflammatory diseases and neoplasia disorders.

1 . A liquid composition comprising at least one human IgG 2  antibody or antigen binding portion thereof, at least one chelating agent, at least one buffer that is histidine, and at least one surfactant, wherein said antibody or antigen binding portion thereof does not comprise a signal sequence. 
     
     
         2 . The composition according to  claim 1 , wherein the at least one chelating agent is EDTA. 
     
     
         3 . The composition according to  claim 1 , wherein the composition further comprises at least one tonicity agent. 
     
     
         4 . The composition according to  claim 1 , wherein the at least one surfactant is polysorbate 80. 
     
     
         5 . The composition according to  claim 1 , wherein the antibody or antigen binding portion is present in an amount from 0.1 mg/mL to 200 mg/mL; the at least one chelating agent is present in an amount from 0.001 mM to 5.0 mM; and the histidine buffer is present in an amount from 1 mM to 100 mM. 
     
     
         6 . The composition according to  claim 1 , wherein the antibody or antigen binding portion is present in an amount from 1 mg/mL to 200 mg/mL; the at least one chelating agent is EDTA and is present in an amount from 0.01 mM to 5.0 mM; and the histidine buffer is present in an amount from 1 mM to 100 mM. 
     
     
         7 . The composition according to  claim 1 , wherein the antibody or antigen binding portion is present in an amount from 1 mg/mL to 200 mg/mL; the at least one chelating agent is EDTA and is present in an amount from 0.01 mM to 1.0 mM; the histidine buffer is present in an amount from 1 mM to 100 mM, the at least one surfactant is present in an amount from 0.01 mg/mL to 10 mg/mL; and the at least one tonicity agent is present in an amount from 100 mM to 400 mM. 
     
     
         8 . The composition according to  claim 7 , wherein the at least surfactant is polysorbate 80. 
     
     
         9 . The composition according to  claim 1 , wherein the at least one tonicity agent is trehalose. 
     
     
         10 . A composition comprising at least one monoclonal human IgG2 antibody or antigen binding portion thereof and a chelating agent, wherein the chelating agent is EDTA and is present in an amount sufficient to stabilize the composition when maintained at a temperature of 40° C. for a period of at least 26 weeks. 
     
     
         11 . The composition according to  claim 10 , wherein the molar ratio of antibody or antigen binding portion to chelating agent ranges from 0.01 to 500. 
     
     
         12 . The composition according to  claim 11 , wherein the molar ratio of antibody or antigen binding portion to chelating agent ranges from 0.05 to 100. 
     
     
         13 . The composition according to  claim 12 , wherein the molar ratio of antibody or antigen binding portion to chelating agent ranges from 0.1 to 10. 
     
     
         14 . The composition according to  claim 13 , wherein the molar ratio of antibody or antigen binding portion to chelating agent ranges from 0.5 to 4. 
     
     
         15 . The composition according to  claim 10 , wherein the composition further comprises histidine in a molar concentration ranging from 1 mM to 100 mM.